VIVUS, Inc. (Nasdaq:
VVUS) today announced a new program offering eligible patients a discount on
Qsymia^® (phentermine and topiramate extended-release) capsules CIV for a
limited time. The Save Now! Program is available online exclusively at
www.qsymia.com and provides patients with the opportunity to pay no more than
$75 for 30 days of the recommended dose (Qsymia 7.5 mg/46 mg). This
represents up to $85 savings off the full retail price (which may vary by
pharmacy) for this once daily therapy.
"We believe our Qsymia offer programs provide more patients struggling with
obesity the opportunity to partner with their physicians to experience the
benefits of Qsymia," said Peter Y. Tam, president of VIVUS. "Our goal is to
take every measure to make Qsymia more accessible to patients today as we
continue to make progress toward achieving reimbursement for patients who
qualify."
Qsymia is the only FDA-approved once daily combination therapy – and the first
medication available in 13 years – for chronic weight management.
To obtain the offer, patients must have a valid prescription issued by a
physician. The offer is limited to one per patient for the duration of the
program. Patients who qualify for the offer program are eligible to receive
30 days of the recommended dose (7.5 mg/46 mg) of Qsymia once daily for no
more than $75.
It is suggested that new patients initiate therapy on the Qsymia starting dose
of 3.75 mg/23 mg for 14 days and then increase to the Qsymia recommended dose
of 7.5 mg/46 mg. This new offer complements the Qsymia Get Started! Free Trial
Program, which provides eligible patients a free trial on a valid prescription
for up to 14 capsules of the Qsymia starting dose (3.75 mg/23 mg). For more
information, visit www.qsymia.com.
* Based on the full retail price of 30 capsules of Qsymia 7.5 mg/46 mg ($85
savings), and the full retail price of 14 capsules of the Qsymia starting
dose, 3.75 mg/23 mg ($65 savings), for a total of $150.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in